Eli Lilly And Co vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Eli Lilly And Co trades at $1,225.52 (market cap $1.08T), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.47. The key difference: Eli Lilly And Co pays a 0.57% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals.
| LLY | SPHD | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | — |
52-Week High | $1.24K | $53.55 |
52-Week Low | $639.43 | $46.96 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
SPHD trades at $52.26, down 0.29% today, with a bullish technical signal supported by moving averages. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income. Recent news highlights investor interest in dividend and value strategies amid market volatility, with articles from Zacks and 24/7 Wall Street in August 2026 emphasizing its role in retirement portfolios.
The outlook for SPHD is stable, appealing for income-focused investors seeking lower volatility. Key opportunities include consistent dividends and defensive positioning, while risks involve interest rate sensitivity and potential underperformance in strong bull markets. Analyst sentiment is generally positive for its strategy in current conditions.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →